Identifying a new factor that helps immune cells clear dead cells in heart disease.
Discovering Wdfy3 as a novel regulator of macrophage efferocytosis by genome-wide CRISPR screen
This study is looking at how a gene called Wdfy3 helps immune cells called macrophages clean up dead cells in the body, which is important for preventing heart diseases, and the findings could lead to new ways to help your body stay healthy by improving this natural cleaning process.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10828837 on NIH RePORTER |
What this research studies
This research investigates how a specific gene, Wdfy3, influences the ability of immune cells called macrophages to clear dead cells, a process known as efferocytosis. By using a genome-wide CRISPR screen, researchers are identifying genes that regulate this process, which is crucial for preventing diseases like atherosclerosis. The study focuses on understanding the molecular mechanisms of Wdfy3 and its role in the degradation of dead cells, which could lead to new therapeutic strategies for heart disease. Patients may benefit from insights gained about how to enhance the body's natural processes for clearing harmful cellular debris.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for or diagnosed with atherosclerotic cardiovascular disease.
Not a fit: Patients with conditions unrelated to atherosclerosis or those who do not have issues with macrophage function may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve the clearance of dead cells, potentially reducing the risk of atherosclerosis and related cardiovascular diseases.
How similar studies have performed: Other research has shown promise in targeting similar pathways for improving immune cell function, suggesting that this approach could yield significant insights.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Zhang, Hanrui — Columbia University Health Sciences
- Study coordinator: Zhang, Hanrui
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.